🚀
Enjoy a 7-Day Free Trial Thru May 08, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
BeiGene Ltd (FRA:49BA)
News
BeiGene Ltd - ADR
FRA
:49BA (Cayman Islands) Â
ADR
€ 144.00
(+0.7%)
Apr 30
P/E:
At Loss
P/B:
4.63
Market Cap:
€ 15.05B
($ 16.04B)
Enterprise V:
€ 12.95B
($ 13.80B)
Volume:
-
Avg Vol (2M):
73.00
Warning! GuruFocus detected 3 Severe warning signs with 49BA.
Try a 7-Day Free Trial
to check it out.
Also Trade In:
Volume:
-
Market Cap €:
15.05B
Market Cap $:
16.04B
PE Ratio:
At Loss
Avg Vol (2M):
73.00
Enterprise Value €:
12.95B
Enterprise Value $:
13.80B
PB Ratio:
4.63
Alerts
Website
Sources
Stock PDF
Dataset
Financial Download
Manual of Stocksâ„¢
Compare
0
Summary
30-Y Financials
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
BeiGene Ltd (FRA:49BA) Stock News, Headlines & Updates
BeiGene Ltd Stock News from GuruFocus
Total 43
1
2
Apr 26, 2024
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
Business Wire
•
10:00am
Apr 24, 2024
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
Business Wire
•
4:00pm
Apr 23, 2024
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Business Wire
•
6:00am
Mar 14, 2024
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
Business Wire
•
4:00pm
Mar 13, 2024
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
Business Wire
•
8:00am
Mar 07, 2024
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
Business Wire
•
5:00pm
Mar 06, 2024
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
Business Wire
•
6:00am
Feb 29, 2024
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Business Wire
•
10:00am
Feb 28, 2024
BeiGene to Present at Upcoming Investor Conferences
Business Wire
•
8:00am
Feb 27, 2024
BeiGene's Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
Business Wire
•
6:00am
Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight
GuruFocus Research
•
11:05pm
Feb 26, 2024
BeiGene Ltd (BGNE) Reports Substantial Revenue Growth and Pipeline Progress in Q4 and Full Year 2023
GuruFocus Research
•
5:32am
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Business Wire
•
5:00am
Feb 06, 2024
Beigene Ltd at JPMorgan Healthcare Conference Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd Investors and Analysts Panel Event Presentation Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd at Morgan Stanley Global Healthcare Conference Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd Investor Research and Development Day Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd at Goldman Sachs Global Healthcare Conference Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd at JPMorgan Healthcare Conference Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd to Discuss Final Results of the ALPINE Trial Late-Breaker Presentation Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd to Discuss Final Results of the ALPINE Trial Q&A Call Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd at Morgan Stanley Global Healthcare Conference Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd at Goldman Sachs Global Healthcare Conference Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd at Cowen Health Care Conference (Virtual) Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd R&D Day Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd to Discuss Interim Analysis of the ALPINE Trial and Data Presented at EHA2021 Call Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd China National Reimbursement Drug List (NRDL) Results Conference Call Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd to Discuss the Company's Early Development Pipeline and Research Call Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd at American Society of Clinical Oncology (ASCO) Virtual Scientific Program Call Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd at JPMorgan Healthcare Conference Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd Update Call: ASPEN Trial Readout Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd Corporate Update: Global Strategic Oncology Collaboration with Amgen Transcript
GuruFocus Research
•
11:18pm
Beigene Ltd at Morgan Stanley Healthcare Conference Transcript
GuruFocus Research
•
11:17pm
Beigene Ltd Update Call Transcript
GuruFocus Research
•
11:17pm
Beigene Ltd Conference Call to Discuss Clinical Data on Zanubrutinib at 15th International Conference on Malignant Lymphoma (ICML) Transcript
GuruFocus Research
•
11:17pm
Total 43
1
2
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news